A Phase 1a/1b Study of NRM-823 as Monotherapy and in Combination With Immune Checkpoint Inhibition in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Status: Recruiting
Location: See all (3) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Have histologically- or cytologically-diagnosed NSCLC (squamous or adenocarcinoma), TNBC, HNSCC, ESCC, esophageal adenocarcinoma, gastric/GEJ adenocarcinoma, cervical, endometrial, or ovarian cancer which is advanced or metastatic.
• Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
• Adequate liver, renal, pulmonary, and cardiac function.
• Adequate hematologic function.
Locations
United States
Tennessee
Normunity Investigational Site
RECRUITING
Nashville
Texas
Normunity Investigational Site
RECRUITING
San Antonio
Virginia
Normunity Investigational Site
RECRUITING
Fairfax
Contact Information
Primary
Judy Schnyder, MBA
judy.schnyder@normunity.com
215-593-7119
Time Frame
Start Date: 2025-10-30
Estimated Completion Date: 2028-10-31
Participants
Target number of participants: 150
Treatments
Experimental: NRM-823
Administered per protocol requirements
Related Therapeutic Areas
Sponsors
Leads: Normunity AccelCo, Inc.